Sungsoon Fang,Jae Myoung Suh,Elizabeth Yu,Olivia Osborn,Denise Lackey,Eiji Yoshihara,Alessia Perino,Sandra Jacinto,Yelizaveta Lukasheva,Annette R. Atkins,Bernd Schnabl,Ruth T. Yu,David A. Brenner,Sally Coulter,Christopher Liddle,Kristina Schoonjans,Jerrold M. Olefsky,Alan R. Saltiel,Michael Downes,Ronald M. Evans,Changtao Jiang,Cen Xie,Fei Li,Limin Zhang,Robert G. Nichols,Kristopher W. Krausz,Jingwei Cai,Yunpeng Qi,Zhong-Ze Fang,Shogo Takahashi,Dhimant Desai,Shantu G. Amin,Andrew D. Patterson,Frank J. Gonzalez

Abstract:1 Nat Med. 2015 Feb;21(2):159–165. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance Sungsoon Fang, Jae Myoung Suh, Shannon M. Reilly, Elizabeth Yu, Olivia Osborn, Denise Lackey, Eiji Yoshihara, Alessia Perino, Sandra Jacinto, Yelizaveta Lukasheva, Annette R. Atkins, Alexander Khvat, Bernd Schnabl, Ruth T. Yu, David A. Brenner, Sally Coulter, Christopher Liddle, Kristina Schoonjans, Jerrold M. Olefsky, Alan R. Saltiel, Michael Downes and Ronald M. Evans Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA. Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA. Department of Medicine, University of California San Diego, San Diego, California, USA. Metabolic Signaling, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Federale de Lausanne, Switzerland. ChemDiv, Inc., San Diego, California, USA. Storr Liver Unit, Westmead Millennium Institute, Sydney Medical School, University of Sydney, Australia. Howard Hughes Medical Institute, Salk Institute for Biological Studies, La Jolla, California, USA. The systemic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to systemic therapy, bile acid release during a meal selectively activates intestinal FXR. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver. However, unlike systemic agonism, we find that Fex reduces diet-induced weight gain, body-wide inflammation, and hepatic glucose production, while enhancing thermogenesis and browning of white adipose tissue (WAT). These pronounced metabolic improvements

INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function

Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis

The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice

Dual activation of bile acid receptors FXR and TGR5 plays a protective role in non‐alcoholic fatty liver disease and atherosclerosis

FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation

Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output

Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.

Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist

<strong><b></b></strong>Impaired Adipose Tissue Expansion Caused by LXR Activation is Associated with Insulin Resistance in HFD Mice

Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Intestinal Farnesoid X Receptor Signaling Promotes Nonalcoholic Fatty Liver Disease

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.